Molecular biology reports · 2026
Ellagic acid and gallic acid combination attenuates pulmonary fibrotic responses in vitro: evidence suggesting involvement of the 5-HT2B/Ca²⁺/inflammatory axis.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wu Chuan, Wang Xiaomeng, Shen Xiangzhi, Liu Dongheng, Huang Shaolin, Wang Wenxi, Peng Lijun, Yin Wenya
Аннотация
BACKGROUND: Pulmonary fibrosis (PF) is a progressive interstitial lung disease driven by aberrant extracellular matrix (ECM) remodeling and alveolar destruction. While serotonin (5-HT) promotes fibrogenesis via the 5-HT2B receptor, pharmacological interventions targeting this specific pathway remain scarce.
METHODS AND RESULTS: Using a spectrum-effect approach, we screened bioactive phenolic acids from Rosa roxburghii Tratt extracts in a TGF-β1-induced A549 cell model. Evaluating ellagic acid (EA), syringic acid (SA), and gallic acid (GA) both individually and in combination revealed that the EA/GA pairing (EG) yielded the most robust anti-fibrotic activity. Specifically, EG restored E-cadherin expression while suppressing key mesenchymal markers, effectively blunting epithelial-mesenchymal transition (EMT) in vitro. At the signaling level, EG treatment correlated with a downregulation of 5-HT2B-associated pathways, alongside marked reductions in oxidative stress and calcium influx. Our data suggest that EG dampens the Gq-PLCβ-IP3R module, limiting both intracellular calcium mobilization and subsequent NFATc1 activation. Concurrently, we observed a suppression of the CaMKII-dependent NF-κB cascade and its downstream pro-inflammatory targets (TNF-α, IL-6, and COX-2).
CONCLUSIONS: These findings indicate that the EG combination alleviates pro-fibrotic responses in A549 cells by disrupting the 5-HT2B/calcium/inflammation axis. Although in vivo validation is required, this plant-derived combination offers a promising multi-targeted therapeutic strategy against pulmonary fibrosis.
METHODS AND RESULTS: Using a spectrum-effect approach, we screened bioactive phenolic acids from Rosa roxburghii Tratt extracts in a TGF-β1-induced A549 cell model. Evaluating ellagic acid (EA), syringic acid (SA), and gallic acid (GA) both individually and in combination revealed that the EA/GA pairing (EG) yielded the most robust anti-fibrotic activity. Specifically, EG restored E-cadherin expression while suppressing key mesenchymal markers, effectively blunting epithelial-mesenchymal transition (EMT) in vitro. At the signaling level, EG treatment correlated with a downregulation of 5-HT2B-associated pathways, alongside marked reductions in oxidative stress and calcium influx. Our data suggest that EG dampens the Gq-PLCβ-IP3R module, limiting both intracellular calcium mobilization and subsequent NFATc1 activation. Concurrently, we observed a suppression of the CaMKII-dependent NF-κB cascade and its downstream pro-inflammatory targets (TNF-α, IL-6, and COX-2).
CONCLUSIONS: These findings indicate that the EG combination alleviates pro-fibrotic responses in A549 cells by disrupting the 5-HT2B/calcium/inflammation axis. Although in vivo validation is required, this plant-derived combination offers a promising multi-targeted therapeutic strategy against pulmonary fibrosis.